Home >> Research Area >>Tyrosine Kinase/Adaptors>>IRAK>> IRAK inhibitor 4

IRAK inhibitor 4

IRAK inhibitor CAS# 1012104-68-5

IRAK inhibitor 4

2D Structure

Catalog No. BCC1657----Order now to get a substantial discount!

Product Name & Size Price Stock
IRAK inhibitor 4: 5mg $782 In Stock
IRAK inhibitor 4: 10mg Please Inquire In Stock
IRAK inhibitor 4: 20mg Please Inquire Please Inquire
IRAK inhibitor 4: 50mg Please Inquire Please Inquire
IRAK inhibitor 4: 100mg Please Inquire Please Inquire
IRAK inhibitor 4: 200mg Please Inquire Please Inquire
IRAK inhibitor 4: 500mg Please Inquire Please Inquire
IRAK inhibitor 4: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of IRAK inhibitor 4

3D structure

Package In Stock

IRAK inhibitor 4

Number of papers citing our products

Chemical Properties of IRAK inhibitor 4

Cas No. 1012104-68-5 SDF Download SDF
PubChem ID 24797387 Appearance Powder
Formula C33H35F3N6O3 M.Wt 620.66
Type of Compound N/A Storage Desiccate at -20°C
Solubility Soluble in DMSO
Chemical Name 1-(4-hydroxycyclohexyl)-N-(3-methylbutyl)-2-[[5-[2-(trifluoromethoxy)phenyl]-1H-indazol-3-yl]amino]benzimidazole-5-carboxamide
SMILES CC(C)CCNC(=O)C1=CC2=C(C=C1)N(C(=N2)NC3=NNC4=C3C=C(C=C4)C5=CC=CC=C5OC(F)(F)F)C6CCC(CC6)O
Standard InChIKey QZMAOGLWCNTFCG-UHFFFAOYSA-N
Standard InChI InChI=1S/C33H35F3N6O3/c1-19(2)15-16-37-31(44)21-8-14-28-27(18-21)38-32(42(28)22-9-11-23(43)12-10-22)39-30-25-17-20(7-13-26(25)40-41-30)24-5-3-4-6-29(24)45-33(34,35)36/h3-8,13-14,17-19,22-23,43H,9-12,15-16H2,1-2H3,(H,37,44)(H2,38,39,40,41)
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of IRAK inhibitor 4

DescriptionIRAK inhibitor 4 is an inhibitor of interleukin- 1 receptor-associated kinase.
TargetsIRAK    

Protocol

Cell Assay [1]
THP-1 cells are grown in RPMI 1640 medium supplemented with 2 mM L-glutamine, 10% heat-inactivated FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin. For monocytic differentiation, cells are seeded in 24-well flat-bottom culture plates at a density of 5×105 cells/well and allowed to adhere and differentiate for 48 h at 37°C in the presence of 100 nM PMA. THP-1 cells are incubated with 0.1 or 1 μM IRAK-4 inhibitor (IRAK inhibitor 1) for 45 min and then stimulated with M. bovis BCG Moreau (MOI 5:1) or E. coli LPS (1 μg/mL). Culture supernatants are collected after 24 h of stimulation and assayed for the concentrations of human TNF-α or IL-12/23p40 by ELISA. For Western blot analysis, cells are incubated with IRAK-4 inhibitor, in the same concentrations described above, for 45 min and then stimulated with M. bovis BCG Moreau (MOI 5:1) or E. coli LPS (1 μg/mL) for 30 min. The cells are then processed for Western blot assay, as described below.

Animal Administration [1]
To evaluate IRAK-4 involvement in mycobacterial infection, IRAK-4+/+ (wild-type), IRAK-4+/- (heterozygous), and IRAK-4-/- (IRAK-4-knockout) mice are used. Eight-week-old mice are infected i.v. with 1×106 CFU of M. bovis strain Moreau. The bacterial loads in the spleens, livers, and lungs are determined at 15, 30, and 60 d postinfection. Briefly, the organs are collected aseptically and homogenized in distilled water that contained 0.05% Tween 80. Serial dilutions of the resulting suspensions are plated on Middlebrook 7H11 agar medium supplemented with 10% oleic acid-albumin-dextrose-catalase, and CFU are counted following a 21-d incubation at 37°C and 5% CO2.

References:
[1]. Marinho FV, et al. Lack of IL-1 Receptor-Associated Kinase-4 Leads to Defective Th1 Cell Responses and Renders Mice Susceptible to Mycobacterial Infection. J Immunol. 2016 Sep 1;197(5):1852-63. [2]. Talreja J, et al. Dual Inhibition of Rip2 and IRAK1/4 Regulates IL-1β and IL-6 in Sarcoidosis Alveolar Macrophages and Peripheral Blood Mononuclear Cells. J Immunol. 2016 Aug 15;197(4):1368-78. [3]. Li Z, et al. Inhibition of IRAK1/4 sensitizes T cell acute lymphoblastic leukemia to chemotherapies. J Clin Invest. 2015 Mar 2;125(3):1081-97.

IRAK inhibitor 4 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

IRAK inhibitor 4 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of IRAK inhibitor 4

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 1.6112 mL 8.0559 mL 16.1119 mL 32.2238 mL 40.2797 mL
5 mM 0.3222 mL 1.6112 mL 3.2224 mL 6.4448 mL 8.0559 mL
10 mM 0.1611 mL 0.8056 mL 1.6112 mL 3.2224 mL 4.028 mL
50 mM 0.0322 mL 0.1611 mL 0.3222 mL 0.6445 mL 0.8056 mL
100 mM 0.0161 mL 0.0806 mL 0.1611 mL 0.3222 mL 0.4028 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on IRAK inhibitor 4

IRAK inhibitor 4 is an inhibitor of interleukin- 1 receptor-associated kinase [1].

IRAK-4 belongs to Interleukin-1 Receptor-Associated Kinase, which are key components in the signal transduction pathways. IRAK-4 is an essential signal transducer downstream of interleukin-1 receptor (IL-1R), interleukin-18 receptor (IL-18R) and Toll-like receptors (TLRs). Inhibition of IRAK-4 can modulate its function, thus toning down inflammatory responses. IRAK inhibitor 4 is an indazole inhibitor. As inhibitors of IRAK-4, imidazo[1,2-b]pyridazines and indazoles are used for treatment of some inflammatory, cell proliferative and immune-related disorders [1].

References:
[1] Zhulun Wang, Holger Wesche, Tracey Stevens, Nigel Walker and Wen-Chen Yeh. IRAK-4 Inhibitors for Inflammation. Current Topics in Medicinal Chemistry. 2009, 9: 724-737.

Featured Products
New Products
 

References on IRAK inhibitor 4

Quantitative structure-activity relationship (QSAR) study of interleukin-1 receptor associated kinase 4 (IRAK-4) inhibitor activity by the genetic algorithm and multiple linear regression (GA-MLR) method.[Pubmed:20429783]

J Enzyme Inhib Med Chem. 2010 Dec;25(6):844-53.

A linear quantitative structure-activity relationship (QSAR) model is presented for the modelling and prediction for the interleukin-1 receptor associated kinase 4 (IRAK-4) inhibition activity of amides and imidazo[1,2-alpha] pyridines. The model was produced using the multiple linear regression (MLR) technique on a database that consisted of 65 recently discovered amides and imidazo[1,2- alpha] pyridines. Among the different constitutional, topological, geometrical, electrostatic and quantum-chemical descriptors that were considered as inputs to the model, seven variables were selected using the genetic algorithm subset selection method (GA). The accuracy of the proposed MLR model was illustrated using the following evaluation techniques: cross-validation, validation through an external test set, and Y-randomisation. The predictive ability of the model was found to be satisfactory and could be used for designing a similar group of compounds.

Description

IRAK inhibitor 4 is an interleukin-1 receptor associated kinase 4(IRAK4) inhibitor.

Keywords:

IRAK inhibitor 4,1012104-68-5,Natural Products,IRAK, buy IRAK inhibitor 4 , IRAK inhibitor 4 supplier , purchase IRAK inhibitor 4 , IRAK inhibitor 4 cost , IRAK inhibitor 4 manufacturer , order IRAK inhibitor 4 , high purity IRAK inhibitor 4

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: